Aditxt announced a transaction to separate its subsidiary Ignite Proteomics into an independent public company named Ignite Proteomics Inc., while Aditxt remains listed on Nasdaq. Ignite focuses on precision oncology, particularly breast cancer, and aims to expand its tumor type coverage. The deal is intended to unlock value for Ignite and provide it with better access to growth capital for commercialization and clinical efforts. Aditxt shares fell about 28% in premarket trading amid weak market sentiment for volatile microcaps, with the stock deeply oversold technically. The transaction awaits shareholder and regulatory approvals before completion.
Leading Japanese companies, startups, and research institutions are developing specialized AI models using NVIDIA Nemotron open models to address Japan's unique language, industrial, and workforce challenges. These AI applications range from enterpri...
ARCpoint Inc. announced it will likely miss the July 29, 2026 deadline to file its annual financial statements and related reports due to a lack of funds to pay auditors. The company has applied for a Management Cease Trade Order (MCTO) and awaits ap...
The Rosen Law Firm is investigating potential securities claims against Putnam Investment Management, LLC, alleging that the company may have provided misleading business information to investors. Investors who purchased Putnam stock-based mutual fun...
Several stocks experienced significant declines today driven by company-specific events. SANUWAVE Health's shares dropped 39.21% despite strong revenue guidance, Twin Vee Powercats fell 30.95% amid a legal investigation, and Gorilla Technology declin...
The phase III ENDURANCE trial showed that two years of lenalidomide maintenance therapy offers the same long-term survival benefit as indefinite treatment for patients with standard-risk multiple myeloma who are not transplant candidates. After nearl...
